# Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies

Source: https://onco.cc/trials/nct07730125/  
OnCo record `nct07730125` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in triple-negative breast cancer, run by CoRegen, Inc., not yet recruiting.

## Summary

Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies is a phase 1/2, interventional study registered as NCT07730125 by CoRegen, Inc., with a registry enrolment figure of 67 participants, started 2026-11 and due to reach its primary completion in 2029-06. Interventions recorded: CRG-150. Conditions listed: HR-positive, HER2-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Prostate Cancer. Triple-negative eligibility wording from the registry: "TNBC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07730125
- Phase: 1/2
- Setting: Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
- Sponsor: CoRegen, Inc.
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT07730125: https://clinicaltrials.gov/study/NCT07730125

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07730125.json